JD.com’s healthcare spinoff has filed for an initial public offering after raising more than $1.9bn in equity funding from investors including Hillhouse Capital and Citic Capital.

UT Southwestern-founded Taysha Gene Therapies surpassed its goal after underwriters bought additional shares.

Tencent has led a round worth hundreds of millions of dollars for New Ruipeng, which is now valued at $4.4bn and also backed by Boehringer Ingelheim and Country Garden.

Roche has injected funding into Palladio, creators of a drug for autosomal dominant polycystic kidney disease.

OUP has injected follow-on funding into Palladio, creators of a drug for autosomal dominant polycystic kidney disease.

SoftBank Vision Fund 2, PICC Group and Morningside Venture Capital co-led the round, which also attracted Tencent, China Life Insurance, SIG China and others.

Tencent joined GL Ventures and YF Capital to co-lead a $176m funding round for Taimei Technology, while SoftBank China Venture Capital also invested.

Lilly Asia Ventures has returned for a $147m series D round that will allow InventisBio to advance its treatments for breast cancer and gout into phase 2 clinical trials.

GV has thrown its weight behind Monte Rosa Therapeutics, which is working on biotechnology to degrade disease-driving proteins that have hitherto been considered undruggable.

University of London-linked Monte Rosa Therapeutics is working on biotechnology to degrade disease-driving proteins that have hitherto been considered undruggable.